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Abstract 
Background: Diabetes, associated with hyperlipidemia and oxidative stress, would lead to an increased production 
of reactive oxygen species. Rehmannia glutinosa (Di Huang) is widely used to nourish yin, invigorate the kidney (shen), 
and treat xiao ke (a diabetes-like syndrome in Chinese medicine). This study aims to investigate the antidiabetic and 
antioxidant effects of catalpol from R. glutinosa on rat diabetes induced by streptozotocin (STZ) and high-fat, high-
sugar feed.
Methods: Rats (eight rats in each group at least) were induced diabetes by an initial high-fat high-sugar feed for 
3 weeks, followed by an intraperitoneal injection of STZ (30 mg/kg) for 3 days, and rats were fasted overnight before 
treatments. Catalpol at a dose of 0, 5, 10, 20 or 50 mg/kg was administrated through bolus intravenous injection to 
the experimental rats to find the most effective anti-hyperglycemic dose of catalpol to further study body weight loss, 
water intake, and food intake. The most effective catalpol dose was given to the diabetic model rats with hyperlipi-
demia, and the levels of blood sugar, plasma total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cho-
lesterol (HDL-C) were measured after catalpol administration once a day for 2 weeks. An oral glucose challenge test 
(OGCT) was performed after above experiments in which the most effective dose of catalpol has been determined. 
Levels of glutathione peroxidase (GSH-PX), catalase (CAT), superoxide dismutase (SOD), and malondialdehyde (MDA) 
were measured by corresponding reagent kits and morphological changes of the pancreas were observed with histo-
pathological examination using H&E stain.
Results: Catalpol at a dose of 50 mg/kg ameliorated body weight loss and increased water and food intake. Catalpol 
also attenuated the increase of plasma TC (P = 0.0067) and TG (P = 0.0084) and increased HDL-C (P = 0.0336). The 
OGCT revealed that catalpol reduced the increase of plasma glucose. The activities of antioxidative enzymes (SOD, 
P = 0.0037; GSH-PX, P = 0.0066; CAT, P = 0.005) were enhanced and MDA was reduced (P = 0.003). Furthermore, 
catalpol reduced the morphological impairment of the pancreas.
Conclusion: Catalpol protected against STZ-induced diabetes with high-fat and high-sugar feed with ameliorated 
structural impairment of the pancreas and restored balance between oxidative enzymes and antioxidative enzymes.
© 2016 Zhu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Diabetes mellitus is a heterogeneous metabolic disorder 
characterized by chronic hyperglycemia. It is associated 
with long-term complications and results in various bod-
ily dysfunctions [1]. Diabetes often leads to the vascular 
complications of coronary artery disease and cerebrovas-
cular disease and can cause renal failure, blindness, limb 
amputation, neurological complications, and premature 
death. With rapid therapeutic advancements, novel treat-
ments with fewer side effects have become more feasible 
for long-term management of this disorder [2].
Rehmannia glutinosa (Di Huang) is a widely used herb 
in Chinese medicine (CM) that belongs to the Scrophu-
lariaceae family. It has a high medicinal value and is taken 
to nourish yin and invigorate the kidney in CM [3]. R. glu-
tinosa is often used to treat xiao ke [4], both xiao ke and 
diabetes patients experience the “3Ps”: polyuria (frequent 
urination), polydipsia (increased thirst), and polyphagia 
(increased hunger). CM theory attributes yin deficiency 
to diabetes [4] and R. glutinosa is often clinically used to 
ameliorate patients’ symptoms.
Catalpol, an iridoid glucoside of R. glutinosa, has 
many biological effects, including anticytotoxic and 
anti-inflammatory properties. Catalpol protected mes-
encephalic neurons from 1-methyl-4-phenylpyridinium 
[MPP(+)]-induced oxidative stress [5]. It also protected 
against hydrogen peroxide-induced apoptosis by pre-
venting cytochrome c release and inactivating the cas-
pase cascade, [6] against hydrogen peroxide-induced 
oxidative damage [7], and against ischemia-induced 
damage in astrocytes. Moreover, in an animal model, 
catalpol treatment ameliorated cognitive deficits and 
attenuated oxidative damage in brains of aging mice 
induced by d-galactose, increased the activities of SOD 
and GSH-PX, and reduced MDA levels in the liver and 
spleen [8].
Recent works have demonstrated catalpol’s anti-hyper-
glycemic effect in streptozotocin (STZ)-induced [2] 
and alloxan-induced rat diabetes [9, 10]. Catalpol could 
increase glucose use to lower plasma glucose in diabetic 
rats lacking insulin [2] through increasing beta-endor-
phin secretion from the adrenal gland in STZ-diabetic 
rats [11]. Moreover, oral supplementation of catalpol 
ameliorates diabetic encephalopathy by attenuating oxi-
dative stress and increasing nerve growth factor con-
centration [1]. It ameliorated diabetic nephropathy [12] 
in rats by reducing the expression of pro-inflammatory 
mediators, such as monocyte chemotactic protein-1, 
tumor necrosis factor-alpha, inducible nitric oxide syn-
thase, and receptors for advanced glycation endproducts 
(AGE). Catalpol suppressed AGE-induced phosphoryla-
tion of mitogen activated protein kinases, degradation 
of IkappaBalpha, and the nuclear localization of nuclear 
factor-kappaB [13]. Most studies of the effects of catalpol 
on diabetes mellitus have used normal diets in experi-
mental models of chemical diabetes. However, type 2 
diabetes mellitus is usually accompanied by glycolipid 
metabolism disorders and the effect of catalpol on type 2 
diabetes mellitus with hyperlipid syndrome after a high-
fat diet is still unknown.
This study aims to investigate the antidiabetic and anti-
oxidant effects of catalpol from R. glutinosa on rat dia-
betes induced by STZ and high-fat, high-sugar feed. STZ 
and alloxan have been used to induce a diabetes mel-
litus model and damage the pancreas. Oxidative stress 
produced by STZ and alloxan is involved in diabetes 
mellitus and catalpol seems to have good anti-oxidative 
stress properties. In the present study, STZ-induced 
diabetes mellitus with a high-sugar and high-fat diet 
was used to imitate human type 2 diabetes mellitus. We 
investigated the effects of catalpol on glucose and fat 
metabolism in STZ-induced diabetic rats and measured 
oxidative enzyme and antioxidative enzyme plasma levels 




STZ was obtained from Sigma-Aldrich Inc. (Sigma, 
S0130, USA). Analytical grade catalpol (product >99  % 
purity) was purchased from Liubobainiao Biotechnol-
ogy Co., Ltd (Shijiazhuang, China). Blood glucose Span 
Diagnostic kit and Jinque test strips was obtained from 
Shanghai MicroSence Inc. (Shanghai, China). Blood lipid 
commercially available kits, CAT, GSH-PX, SOD and 
MDA commercially available kits were from Nanjing 
Jiancheng Bioengineering Institute (China).
Experimental animals and feeds
One hundred twenty male Wistar rats (200–250 g) were 
procured from the Experimental Animal Center, Chong-
qing Medical University, China. The rats were arbitrarily 
divided into four groups: normal group (n  =  8), high-
sugar and high-fat feed (high-fat, n = 8) group, STZ-dia-
betic animals with high-sugar and high-fat feed (STZ-fat, 
n =  12), and STZ-diabetic animals with high-sugar and 
high-fat feed treated with catalpol (STZ-fat-cat, n = 12).
Rats were kept in an air-conditioned room maintained 
at a constant temperature (24–26  °C) and humidity 
(50–60  %) under a 12-h light/dark cycle (07:00 on and 
19:00 off). Standard rat feed and water were provided 
ad  libitum. The rats were allowed to acclimatize to the 
laboratory environment for 7  days before the start of 
the experiment. All experimental procedures were con-
ducted in conformity with institutional guidelines for 
the care and use of laboratory animals in China (Permit: 
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SCXK 2002A040), and the international guidelines on 
the ethical use of animals (NIH publications No. 80–23, 
revised 1996).
The high-sugar, high-fat diet was comprised of normal 
diet 54 kg, sucrose 16.5 kg, lard 8.31 kg, egg yolk 4.14 kg, 
and salt 83.4 g, with a total combined weight of 83.784 kg 
[14, 15]. The normal diet was purchased from Beijing 
China Fukang Biotechnology Co., Ltd (Beijing, China). 
The main components of the normal diet were crude pro-
tein ≥18 %, crude fat ≥4 %, crude fiber ≥5 %, crude ash 
≤8 %, moisture ≤10 %, lysine ≥0.82 %, calcium 1–1.8 %, 
phosphorus 0.6–1.2 %, and salt 0.2–0.8 %.
Induction of diabetes in rats
Diabetes was induced by an initial high-sugar and high-
fat feed for 3 weeks, followed by an intraperitoneal injec-
tion of STZ (30  mg/kg) for 3  days. STZ was dissolved 
in a freshly prepared 0.01 M citrate buffer (pH 4.5). The 
normal control group was injected with buffer alone. Rats 
with blood glucose ≥16.7 mmol/L for 3 weeks were con-
sidered as diabetic [16] and the death rates for modeling 
of STZ-fat were 22–28 %.
Experimental design and catalpol treatment of rats
At the first stage, catalpol was injected into the rat tail 
vein at a dose of 0, 5, 10, 20, or 50 mg/kg. Blood was col-
lected after catalpol treatment for 14  days to assess the 
blood glucose-lowering effect of catalpol.
At the second stage, the most effective dose of catal-
pol was selected for further study. The plasma lipid level 
was detected in the normal, high-sugar and high fat 
feed, STZ-fat, and STZ-fat-cat groups at 14  days after 
treatment with catalpol. The plasma in each group was 
collected and then antioxidative enzymes such as GSH-
PX, SOD, CAT, and the MDA oxidative products were 
detected with corresponding kits. Oral glucose challenge 
tests (OGCT) were then performed on experimental 
rats using a Roche blood glucose monitor (Roche Diag-
nostics, Rotkreuz, Switzerland.) with Jinque test strips. 
During the experiment, body weight, food intake, and 
water intake were recorded every 2 days. Finally, a splenic 
portion of pancreatic tissue was removed immediately 
after sacrifice to observe morphological changes of the 
pancreas.
Determination of plasma glucose
Blood samples were collected from the inner canthus 
using a capillary tube under chloral hydrate anesthesia 
at each time point. Concentration of blood glucose was 
determined by a glucose meter (Roche Diagnostics, Rot-
kreuz, Switzerland) with Jinque test strips (Span Biotech 
Ltd, India).
Plasma collection and biochemical determination
Blood samples were collected from the inner canthus 
using a capillary tube under chloral hydrate anesthesia 
after catalpol treatment for 14  days. The samples were 
centrifuged at 2810×g for 10  min at 4  °C within 1  h 
after collection, and then supernatants were collected. 
The concentration of plasma total cholesterol (TC), tri-
glyceride (TG), and high-density lipoprotein cholesterol 
(HDL-C); the activities of SOD, GSH-PX, CAT and the 
concentration of MDA were determined by a series of 
commercially available kits including SOD, GSH-PX, 
CAT, and MDA kits (Nanjing Jiancheng Bioengineer-
ing Institute, China) according to the manufacturers’ 
instructions.
Oral glucose challenge test
An OGCT was performed according to a method pre-
viously described with minor modifications [17–19]. 
Briefly, catalpol at the most effective dose, or the same 
volume of vehicle, was injected intravenously into rats 
for 14  days. Then a glucose dose of 2.5  g/kg was intra-
gastrically administrated to the rats. Blood samples were 
collected sequentially from the tail vein before (0 h) and 
0.5, 1, 2, 3, 5, 7, and 9 h post challenge. Plasma glucose 
changes at the indicated time were determined with a 
glucose meter (Accu-Chek, Switzerland) and Jinque test 
strips.
Histological evaluation of pancreas with hematoxylin 
and eosin (H&E) staining
A splenic portion of pancreatic tissue was removed 
immediately after sacrifice and rinsed with ice-cold 
saline. The tissue samples were fixed in 4 % buffered neu-
tral paraformaldehyde solution overnight, embedded in 
paraffin, and deparaffinized using standard procedures 
[20, 21]. Thin Sections (5 µm) were dewaxed, dehydrated 
in a graded series of ethanol, and rehydrated, then stained 
with H&E for light microscopic examination (Leica, Ger-
many). All histological analyses were performed in arbi-
trarily selected fields in sections by two investigators 
blinded to the identity of the treatment groups.
Statistical analysis
All data were analyzed by the SPSS statistical software 
(version 13.0, SPSS, Chicago, IL, USA), with P < 0.05 val-
ues were considered as statistically significant. Results 
were expressed as mean ± standard deviation (SD). Com-
parisons between the groups were assessed by paired-
samples t test, and P value correction for multiple group 
comparison by LSD-t test. Dose-dependent manner of 
catalpol’s hyperglycemic action was visually determined 
from a dose–response curve.
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Results
Dose‑dependent anti‑hyperglycemic action of catalpol
Catalpol at higher doses lowered plasma glucose con-
centrations more effectively in STZ-fat-diabetic rats. A 
dose-dependent increase of anti-hyperglycemic activity 
was observed in STZ-fat-diabetic rats upon intravenous 
injection of catalpol at the dose range 10–50  mg/kg for 
2 weeks (Fig. 1). There was no additional effect of catal-
pol with an increase in dosage beyond 50  mg/kg. The 
minimal and maximal plasma glucose-lowering activities 
of catalpol in STZ-fat-diabetic rats were 21.7 ± 1.3 % at 
10 mg/kg and 65.8 ± 3.07 % at 50 mg/kg.
Effects of catalpol on body weight
As shown in Fig. 2, after adaptation feed for 1 week, and 
then high-fat and high-sugar feed for 3 weeks, the initial 
body weight and the body weight increase in each group 
were similar. After administration of STZ, the body 
weight of the STZ-fat-diabetic rats continued to reduce. 
At the end of the study, the diabetic rats in all groups 
had lost body weight even when compared with their 
weight after high-fat and high-sugar feeding for 3 weeks 
(P = 0.047). However, the final body weight in the catal-
pol group was significantly greater than the body weight 
in the STZ-fat-diabetic rats (P = 0.009) and was close to 
the starting weight.
Effects of catalpol on feed consumption
After adaptation feed for 1 week, and high-fat and high-
sugar feed for 3 weeks, food intake starting in the high-
fat and high-sugar feed period increased quickly in the 
first 2  weeks, then began to decrease, and increased 
obviously when STZ was given to induce diabetes in the 
STZ-fat-diabetic group (Fig. 3). When catalpol was given 
for 4 days, the food intake obviously reduced compared 
with that of STZ-fat-diabetic rats administered with same 
volume of vehicle (P =  0.045), and continued to reduce 
for 14 days after catalpol treatment (P = 0.020–0.045).
Fig. 1 Anti-hyperglycemic action of catalpol for 2 weeks in STZ-dia-
betic rats with high-sugar and high-fat diet. Values (mean ± SD) were 
obtained from eight animals through intravenous injection (iv) of 
catalpol at the indicated dose. *P = 0.02, **P = 0.005 and ***P < 0.001 
as compared with no treatment values (0 mg/kg)
Fig. 2 Effects of catalpol on body weight gains of rats. After given 
high-sugar high-fat food for 3 weeks, and STZ induced STZ-fat-
diabetic rats successfully for 3 weeks, a solution of catalpol at 50 mg/
kg or the same volume of vehicle was injected intravenously into rats. 
Changes of body weight at the indicated time point were compared 
between the catalpol-treated group (solid circles) and the vehicle-
treated group (open circles). Values (mean ± SD) of each group were 
obtained from eight animals. *P = 0.047 and **P = 0.009 as com-
pared with vehicle-treated group at the same time
Fig. 3 Effect of catalpol on food consumption of rats. After given 
high-fat high-sugar food for 3 weeks, and STZ induced STZ-fat-
diabetic rats successfully for 3 weeks, a solution of catalpol at 50 mg/
kg or the same volume of vehicle was injected intravenously into rats. 
Changes of food intake at the indicated time point were compared 
between the catalpol-treated group (solid circles) and the vehicle-
treated group (open circles). Values (mean ± SD) of each group were 
obtained from eight animals. *P < 0.05 as compared with vehicle-
treated group at the same time
Page 5 of 10Zhu et al. Chin Med  (2016) 11:25 
Effects of catalpol on water intake
As shown in Fig. 4, after adaptation feed for 1 week, and 
then high-fat and high-sugar feed for 3  weeks, water 
intake increased quickly starting in the high-fat and 
high-sugar feed period, and continued to increase for 
3 weeks after STZ-fat-diabetes was successfully induced. 
After catalpol treatment for 6, 8, and 10 days, the water 
intake obviously reduced compared with water intake 
in the STZ-fat-diabetic rats administered with the same 
volume of vehicle (P = 0.05, 0.034, 0.048, respectively). 
At 12 and 14  days, water intake reduced significantly 
compared with the control rats (P  =  0.0087, 0.0089, 
respectively).
Anti‑hyperglycemic action of catalpol in rat diabetes 
induced by STZ with high‑sugar and high‑fat feed
No group differences in plasma sugar were found before 
STZ administration (Fig.  5). Plasma sugar reached 
16.7 mmol/L for 1 week after STZ was given, and plasma 
sugar in each group became gradually elevated. How-
ever, plasma sugar decreased significantly after catalpol 
(50 mg/kg) treatment for 2 weeks, compared with that of 
the STZ-fat-diabetic rats (P = 0.0031), and plasma sugar 
recovered to the level before STZ administration.
Anti‑hyperlipid action of catalpol
As shown in Fig.  6, TC and TG were obviously ele-
vated in rats given the high-fat and high-sugar diet for 
3  weeks compared with the normal group (P  =  0.036, 
0.04, respectively) and HDL-C decreased significantly 
(P  =  0.045). After STZ administration, TC and TG 
increased remarkably (P = 0.0067, 0.0058, respectively) 
compared with those of the high-fat group and the 
HDL-C in the high-fat group was reduced compared 
with that of the normal group (P  =  0.044). STZ-fat-
diabetic rats treated with catalpol (50  mg/kg) showed 
Fig. 4 Effect of catalpol on water intake of rats. After given high-fat 
high-sugar food for 3 weeks, and treatment by STZ for 3 days induced 
STZ-fat-diabetic rats successfully for 3 weeks. A solution of catalpol at 
50 mg/kg or the same volume of vehicle was injected intravenously 
into rats. Changes of water intake at the indicated time point were 
compared between the catalpol-treated group (solid circles) and 
the vehicle-treated group (open circles). Values (mean ± SD) of each 
group were obtained from eight animals. *P < 0.05 and **P < 0.01 as 
compared with vehicle-treated group at the same time
Fig. 5 Anti-hyperglycemic action of catalpol for 2 weeks in STZ-
diabetic rats with high-sugar and high-fat feed. Values (mean ± SD) 
were obtained from eight animals through intravenous injection (iv) 
of catalpol at 50 mg/kg dose. *P = 0.0031 as compared with non-
treated group (saline)
Fig. 6 Anti-hyperlipid action of catalpol for 2 weeks in STZ-diabetic 
rats with high-sugar and high-fat feed. Values (mean ± SD) were 
obtained from eight animals through intravenous injection (iv) of 
catalpol at 50 mg/kg dose. #P < 0.05 vs. normal; ##P < 0.01 vs. high fat 
group and *P < 0.05 vs. STZ-fat group
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significantly attenuated TC (P  =  0.0067) and TG 
(P = 0.0084) compared with the high-fat group. The level 
of HDL-C obviously increased (P  =  0.0336), although 
TC, TG, and HDL-C levels did not all return to normal.
Effects of catalpol on the oral glucose challenge test 
in STZ‑fat‑diabetic rats
An OGCT was then carried out to determine the glucose 
clearance. The plasma glucose concentration was elevated 
in both vehicle- and catalpol-treated rats 30  min after 
oral glucose administration (Fig. 7). However, there were 
no statistically significant differences in plasma glucose 
concentration between the catalpol group and the vehicle 
group within 3  h after treatment. The increased plasma 
glucose induced by the oral glucose was significantly lower 
in the rats at 3 h in the catalpol group compared with the 
vehicle-treated rats (P = 0.046), and this pattern continued 
for 5 h (P = 0.0076), 7 h (P < 0.001), and 9 h (P < 0.001), 
finally returning to normal. It means that significantly 
higher plasma glucose concentrations were detected in 
the vehicle-treated group at 3, 5, 7, and 9 h time points as 
compared to that in the catalpol group. This suggested that 
catalpol could enhance glucose use in vivo.
Effects of catalpol on oxidative stress in STZ‑treated 
diabetic rats
The activities of antioxidative enzymes and the MDA 
plasma concentrations were shown in Fig. 8. There were 
no significant differences in oxidative stress between the 
high-fat and the normal group, although a rising trend in 
MDA and a decreasing trend in GSH-PX, SOD, and CAT 
activity were found in the high-fat group. The activities 
of GSH-PX, SOD, and CAT (P  =  0.008, 0.002, 0.007, 
respectively) in STZ-treated diabetic rats were signifi-
cantly lower than in the normal control rats and high-fat 
rats, while the concentration of MDA (P = 0.006)in STZ-
treated diabetic rats was significantly greater than in the 
normal control rats. Catalpol significantly improved the 
activities of antioxidative enzymes and decreased MDA 
concentration.
Effect of catalpol on morphological changes of the 
pancreas
Only minimal pancreatic histological changes were 
observed in the high-fat group, compared with normal 
pancreatic tissue (Fig.  9a). Minimal inflammatory cells 
were infiltrated into the intralobular area and around 
the pancreatic ducts (Fig. 9b). However, in the STZ-fat-
diabetic group, the pancreatic ducts were hypertense and 
markedly dilated, there was much infiltration of inflam-
matory cells in the intralobular and periductal areas, the 
exocrine glands of the pancreas were atrophic, and the 
fibrotic areas were markedly distributed around the pan-
creatic ducts in the interlobular and intralobular areas 
(Fig. 9c). In contrast, distribution of fibrosis and inflam-
matory cells was markedly attenuated in the STZ-fat-cat 
group and there was no pancreatic ductal hypertension 
and dilation (Fig. 9d).
Fig. 7 Effect of catalpol on plasma glucose levels in STZ-fat diabetic 
rats in an oral glucose challenge test. A solution of catalpol at 50 mg/
kg or the same volume of vehicle was intragastrically administrated 
into rats. Then, a glucose dose of 2.5 g/kg was intragastric administra-
tion into each rat. Changes of plasma glucose at the indicated time 
were compared between the catalpol-treated group (solid circles) and 
the vehicle-treated group (open circles). Values (mean ± SD) of each 
group were obtained from eight animals. *P < 0.05, **P < 0.01, and 
***P < 0.001 as compared with vehicle-treated group at the same 
time
Fig. 8 Effect of catalpol on the activities of antioxidant enzymes 
and the concentration of MDA in the plasma. *P < 0.05, **P < 0.01 vs. 
normal group, #P < 0.05, ##P < 0.01 vs. STZ-treated group
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Discussion
In this study, STZ-induced type 2 diabetes with a high-
fat and high sugar diet was used to study the antidiabetic 
and antioxidant effects of catalpol. STZ is synthesized by 
Streptomycetes achromogenes and is used to induce both 
insulin-dependent and non-insulin-dependent diabetes 
mellitus based on the STZ dose [22, 23]. The most fre-
quently used single intravenous dose to induce insulin-
dependent diabetes mellitus in adult rats is between 40 
and 60 mg/kg by body weight [24]. STZ is also efficacious 
after intraperitoneal administration of a similar or higher 
dose, but a single dose below 40 mg/kg body weight may 
be ineffective [25]. STZ can also be given in multiple low 
doses. In this paper, rat diabetes was induced by a small 
dose of STZ (30 mg/kg) for 3 days after the rats were given 
high-fat and high-sugar feed for 3  weeks; this modeled 
more closely human type 2 diabetes because it accom-
panied the lipid abnormality. Before STZ administration, 
rats were given a high-sugar and high-fat diet for 3 weeks 
to induce fat and lipid abnormities, and their fasting blood 
sugar was near normal (less than 7 mmol/L). The plasma 
sugar and lipids were high after STZ administration for 
2  weeks. STZ-diabetic body weight obviously decreased 
and was accompanied by increased thirst, frequent urina-
tion, and increased hunger. These changes indicated dia-
betes was successfully induced.
c d
ba
Fig. 9 Representative light microscopic appearances of the pancreas stained with H&E (200x) (a–d). a Normal histological changes were observed 
in the normal group on day 14. b Only minimal histological changes were observed in the control (high-fat and high-sugar) group on day 14. c The 
pancreatic ductal hypertension STZ-fat-diabetic rats group, infiltration of inflammatory cells were found in the interlobular and periductal areas on 
day 14. The pancreas was atrophic, and fibrosis and inflammatory cells were markedly distributed in the interlobular and interlobular areas. d In con-
trast, distributions of inflammatory cells and fibrosis were slightly noted Leukocyte infiltration in the catalpol group on day 14. The arrows represent 
inflammatory cells infiltration
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We found that catalpol had positive effects on type 2 dia-
betes. A dose-dependent anti-hyperglycemic action was 
observed for intravenous injection of catalpol at the dose 
range 10–50  mg/kg for 2  weeks. An increase in dosage 
beyond 50 mg/kg produced no additional effects. We chose 
a catalpol dose of 50  mg/kg for further study. The data 
showed that diabetic rats consumed more food and water 
and lost body weight. Interestingly, 50 mg/kg catalpol treat-
ment for 2  weeks significantly ameliorated body weight 
loss and attenuated water intake and food consumption. 
Although we did collect urine or measure urine volume 
in each group, STZ-fat-diabetes rats became increasingly 
thinner, and the padding was often wet, which meant diu-
resis was markedly obvious in STZ-fat-diabetic rats; how-
ever, catalpol obviously ameliorated these changes.
As a glucose load test, the OGCT was used to test glu-
cose clearance, which reflects pancreatic β cell function. 
Catalpol treatment 3 h after oral glucose administration 
obviously reduced plasma glucose and levels returned to 
normal in 6  h. The OGCT results showed that catalpol 
treatment improved diabetic rats’ ability to adjust blood 
sugar, perhaps through improved islet β cell function. 
Histological evaluation of the pancreas showed clearly 
(Fig. 9c) that the pancreatic tissue was atrophic with the 
presence of fibrosis. There was infiltration of inflamma-
tory cells and these were markedly distributed in the 
interlobular and intralobular areas, but there was mini-
mal distribution of inflammatory cells and fibrosis in the 
catalpol group. These results indicate that catalpol might 
facilitate glucose uptake, which is in accordance with 
previous findings [2].
Diabetes can cause glucose-lipid metabolism distur-
bance. Many diabetes patients show long-term abnormal 
lipid metabolism. In this study, the animal model induced 
by STZ with high-sugar and high-fat feed was close to 
human diabetes type 2. The rat model indicated that 
high-sugar and high-fat food with STZ produced type 2 
diabetes accompanied by lipid metabolism disturbances 
with increases in TC and TG and decreases in HDL-
C. Catalpol lowered plasma TC and TG and increased 
HDL-C (Fig.  5) when the blood sugar was lowered 
(Fig. 6). Catalpol not only ameliorated abnormal glucose 
tolerance, but also relieved the glucose-lipid metabolism 
disturbance.
Oxidative stress plays an important role in diabetes 
mellitus induced by STZ. STZ enters β cells via a glu-
cose transporter and causes alkylation of DNA. DNA 
damage induces the activation of poly adenosine diphos-
phate-ribosylation, a process that is more important 
for the diabetogenicity of STZ than DNA damage itself 
[26]. Poly adenosine diphosphate-ribosylation leads to 
the depletion of cellular nicotinamide adenine dinucleo-
tide and adenosine triphosphate. Enhanced adenosine 
triphosphate dephosphorylation after STZ treatment 
supplies a substrate for xanthenes oxidase resulting in 
the formation of superoxide radicals, hydrogen perox-
ide and hydroxyl radicals. Furthermore, STZ liberates 
toxic amounts of nitric oxide that inhibit aconitase activ-
ity and contribute to DNA damage. STZ can cause β cell 
necrosis [22, 23, 26]. In addition to a plasma lipid and 
sugar increase in STZ-fat-diabetic rats, the present find-
ings show that endogenous antioxidants, such as SOD, 
GSH-PX, and CAT, were decreased and MDA levels 
were increased, which indicates that oxidative stress was 
strengthened in STZ-fat-diabetic rats. However, catal-
pol at 50  mg/kg for 2  weeks significantly reversed the 
lowered antioxidant levels and the increase of oxidative 
stress induced by STZ with sugar-lipid abnormities. SOD, 
GSH-PX, and CAT in plasma increased and MDA levels 
reduced to recover the balance of endogenous oxidants 
and antioxidants. The main active ingredients of catal-
pol, which is an iridoid glucoside, are isolated from the 
roots of R. glutinosa and used for treatment of diabetes 
and its complications. Furthermore, catalpol is a strong 
antioxidant [5, 27, 28] used to treat aging, stroke, and 
demyelination disease. The main effects of catalpol are on 
endogenous oxidant damage [1, 6, 7, 28] and inflamma-
tory reactions [29, 30]. The antioxidant effects of catalpol 
found here are in accord with previous findings [1, 6, 7, 
28]. However, catalpol possessed a stronger anti-inflam-
matory action and reduced inflammatory cytokines in 
senescent mice [29, 30], inhibited lipopolysaccharide 
plus interferon-gamma-induced inflammatory responses 
in astrocyte primary cultures [29, 30], and suppressed 
advanced glycation end-products-induced inflammatory 
responses through the inhibition of reactive oxygen spe-
cies [13]. Based on the anti-hyperglycemic effect of catal-
pol and anti-hyperlipid abnormal coupling with markedly 
reduced oxidative stress in plasma, morphological pan-
creatic changes were examined by a light microscope 
(Fig. 9) after treatment with catalpol. Pancreatic damage 
induced by STZ was manifested as inflammation: infiltra-
tion of inflammatory cells was noted in the hypertension 
and markedly dilated intralobular and periductal areas. 
The atrophic, fibrotic, and inflammatory cells were mark-
edly distributed in the interlobular and intralobular areas 
(Fig. 9c). After treatment with catalpol for 14 days, injury 
was ameliorated and blood glucose was decreased, and 
lipid levels also decreased as catalpol attenuated oxida-
tive stress in STZ-fat-diabetic rats. In addition, inflam-
matory cells and fibrosis were minimal (Fig. 9d) and the 
pancreatic morphological changes were similar to those 
of the high-fat, high-sugar group (Fig. 9b). This suggests 
that catalpol might improve insulin levels in plasma 
through mitigation of pancreas inflammation induced by 
STZ and preserve pancreas islet structure and function.
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We observed protective effects of catalpol on STZ-
fat-diabetic rats. To date, only two studies have inves-
tigated the effect of catalpol on STZ-induced diabetes; 
these have focused on catalpol’s actions on prevent-
ing diabetic encephalopathy [1] and lowering plasma 
glucose through increasing muscle glucose use [2]. To 
our knowledge, this is the first study to investigate the 
effect of catalpol on diabetes induced by STZ with a 
high-sugar and high-fat diet. Catalpol reduced the 
damage to the pancreas in STZ-fat-diabetic rats. Catal-
pol’s protective effects are mainly related to decreased 
oxidative stress and the attenuation of the “3P” symp-
toms in a severely diabetic animal model. Further 
mechanisms of action, such as those involving insulin 
or glycated hemoglobin levels, should be investigated 
further.
Conclusion
Catalpol protected against STZ-induced diabetes with 
high-fat and high-sugar feed with ameliorated struc-
tural impairment of the pancreas and restored balance 
between oxidative enzymes and antioxidative enzymes.
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